Trial Profile

A randomized controlled trial of the effects of low dose zoledronic acid on bone density in osteopenic postmenopausal women

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoledronic acid (Primary)
Indications Bone resorption; Postmenopausal osteoporosis
Focus Therapeutic Use
Acronyms LoDoZe

Most Recent Events

11 Sep 2017 Results of 3 years open label extension of the core trial published in the CMAJ: Canadian Medical Association Journal
09 Nov 2011 Results published in the Journal of Clinical Endocrinology and Metabolism.
01 Jul 2009 Additional lead trial centre Health Research Council of New Zealand identified as reported by Australian New Zealand Clinical Trials Registry record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com